Reviewer’s report

Title: Development of a miRNA-seq Based Prognostic Signature in Lung Adenocarcinoma

Version: 0 Date: 12 Oct 2018

Reviewer: Feng Jiang

Reviewer's report:

Lung cancer is the #1 cancer killer. Of lung cancer cases, adenocarcinoma is a major type. The development of approaches that can predict the outcome of the patients will help personalized treatment of the deadliest disease and thus is clinically important.

The research team develops a miRNA-seq Based Prognostic Signature that can be used as a reliable tool for identifying high-risk subjects. The finding is potentially useful in the clinical settings for patient care.

The major strengths include:

1. Taking advantages of the Cancer Genome Atlas to identify potential candidates.
2. By utilizing a stepwise variable selection procedure to optimize five miRNAs that could be easily applied to the clinics.
3. Using KEGG pathway analysis they further found potential evidence supporting for their significance in multiple cancer pathways.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review? If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics.

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

Lung cancer is the #1 cancer killer. Of lung cancer cases, adenocarcinoma is a major type. The development of approaches that can predict the outcome of the patients will help personalized treatment of the deadliest disease and thus is clinically important.

The research team develops a miRNA-seq Based Prognostic Signature that can be used as a reliable tool for identifying high-risk subjects. The finding is potentially useful in the clinical settings for patient care.

The major strengths include:
1. Taking advantages of the Cancer Genome Atlas to identify potential candidates.
2. By utilizing a stepwise variable selection procedure to optimize five miRNAs that could be easily applied to the clinics.
3. Using KEGG pathway analysis they further found potential evidence supporting for their significance in multiple cancer pathways.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal.